Delphia Therapeutics Named to Boston Business Journal’s 2025 Best Places to Work
View
Press Releases
and News
BIOSPACE: Delphia Eyes New Precision Medicine Approach: Activation Lethality
View
Delphia Therapeutics Named to BioSpace’s Next Gen: Class of 2025
View
Biotech Week Boston Awards: Delphia Therapeutics Wins “Boston Highlight” 2024 Award
View
GENETIC ENGINEERING NEWS: The Upside Down: Delphia Therapeutics Launches to Treat Cancer with Activation Lethality
View
ENDPOINTS: Biotech vets raise $67M to develop targeted activators for cancer
View
TIMMERMAN REPORT: Delphia Raises $67M to Nudge Cancer Cells Beyond the Red Line
View
Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality
View
ENDPOINTS: For decades, cancer drug developers have focused on inhibition. Now, a GV-backed startup is eyeing activation
View
NATURE GENETICS: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities
View
We are bold, courageous,
big-picture thinkers.
With a shared sense of purpose and urgency, our distinguished team brings significant track records of progressing new cancer medicines from discovery through clinical development, regulatory approval and commercialization.
